• About us
    • Who we are
    • Our strategy
    • How we are funded
    • Our people
    • Reports and statements
    • Governance and structure
    • Our impact
  • Working with us
    • Support for MRC researchers
    • Helping charities
    • Our partners
    • Advise & Connect: Covid-19
    • Licensing opportunities
  • Funding
    • LifeArc Ventures
    • Rare disease research funding
    • Development Gap Fund
  • Capabilities
    • Drug discovery
    • Antibody engineering
    • IP management and technology transfer
    • Diagnostics development
  • Careers
    • Jobs
    • Industrial Placements
    • Fellowships
  • News
    • Latest news
    • Case studies
    • Reports and publications
    • Newsletter
    • Covid-19 Information
    • Media contacts
  • Contact us

News

About
Our ventures team
Portfolio companies
News
Contact
News Releases 17 May 2022

LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2

AstraZeneca granted exclusive worldwide licence to develop, manufacture and commercialise RQ Bio’s existing early-stage monoclonal antibodies (mAbs)…

News Releases 2 December 2021

LifeArc participates in Series A funding round for company developing pioneering new gene therapies for neurodegenerative diseases

Helping to progress an innovative gene therapy platform from the bench to a stage where it is progressing closer to the clinic.

News Releases 16 November 2021

LifeArc unveils new strategy and £1.3 billion spend to drive life-changing science

Aims to transform the way diseases such as motor neurone disease are prevented, identified and treated.

News Releases 4 November 2021

10 new data-driven health companies selected for KQ Labs accelerator programme

10 innovative start-up companies working at the interface of biomedical and data science are to receive personalised…

News Releases 3 November 2021

LifeArc invests in company developing personalised drug and digital combination treatments

LifeArc and partners announce a £13 million financing deal in Closed Loop Medicine to enable the company to develop further and faster.

News Releases 25 October 2021

Three new Trustees bring more skills and experience to LifeArc

A very warm welcome to three new Trustees who have joined our Board.

News Releases 4 May 2021

LifeArc invests in Cumulus Neuroscience

Investment part of £6 million funding round led by Dementia Discovery Fund, supported by UK Future Fund

News Releases 22 December 2020

LifeArc co-leads £6 million funding in DJS Antibodies

LifeArc announces Seed Fund investment of £2 million in DJS Antibodies, a biotech start-up company pioneering the…

News Releases 23 September 2020

LifeArc and Future Fund provide £3.0m in funding to Avvinity Therapeutics

Funding to help drive the development of new cancer therapies

  • 1
  • 2
  • >
Quick links
  • Newsletter
  • Media contacts
  • Privacy policy
  • Cookie policy
  • Modern slavery statement
  • Sitemap
Follow us
Get in touch
Lynton House
7-12 Tavistock Square
London WC1H 9LT UK

+44 (0)20 7391 2700
LifeArc is a charity registered with the Charity Commission for England and Wales no. 1015243 and a charity registered in Scotland with the Office of the Scottish Charity Regulator no. SC037861. LifeArc is a company limited by guarantee no. 2698321 incorporated in England and Wales. | © LifeArc 2022
Web design by TWK